WallStSmart

Novartis AG ADR (NVS)vsTurn Therapeutics Inc. Common Stock (TTRX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

NVS leads profitability with a 17.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 48/100 (D+).

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

TTRX

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 2/9Altman Z: -3.15
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-68.3%)

Margin of Safety

-68.3%

Fair Value

$95.56

Current Price

$164.98

$69.42 premium

UndervaluedFair: $95.56Overvalued

Intrinsic value data unavailable for TTRX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS4 strengths · Avg: 9.5/10
Market CapQuality
$303.67B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.3%10/10

Strong operational efficiency at 34.3%

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

TTRX0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.4x4/10

Trading at 8.4x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

TTRX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$316.43M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.

Bull Case : TTRX

TTRX has a balanced fundamental profile.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Bear Case : TTRX

The primary concerns for TTRX are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 8.91 is elevated, increasing financial risk.

Key Dynamics to Monitor

NVS is growing revenue faster at 4.7% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

NVS scores higher overall (48/100 vs 17/100), backed by strong 17.5% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Turn Therapeutics Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Turn Therapeutics Inc., is a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company is headquartered in Westlake Village, California.

Want to dig deeper into these stocks?